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ABSTRACT
Traumatic injuries involving the face are very common, yet the clinical management of the resulting
craniofacial deficiencies is challenging. These injuries are commonly associatedwithmissing teeth, for
which replacement is compromiseddue to inadequate jawbonesupport.Using cell therapy,we report
theupper jaw reconstruction of apatientwho lost teeth and75%of the supporting jawbone following
injury. Amixed population of bonemarrow-derived autologous stemandprogenitor cellswas seeded
ontob-tricalcium phosphate (b-TCP), which served as a scaffold to deliver cells directly to the defect.
Conditions (temperature, incubation time) to achieve the highest cell survival and seeding efficiency
were optimized. Fourmonths after cell therapy, conebeamcomputed tomography andabone biopsy
wereperformed, andoral implantswereplaced to support anengineereddental prosthesis. Cell seed-
ing efficiency (>81%) of the b-TCP and survival during the seeding process (94%) were highest when
cells were incubatedwithb-TCP for 30minutes, regardless of incubation temperature; however, at 1
hour, cell survival was highest when incubated at 4°C. Clinical, radiographic, and histological analyses
confirmed that by 4months, the cell therapy regenerated 80%of the original jawbone deficiencywith
vascularized, mineralized bone sufficient to stably place oral implants. Functional and aesthetic re-
habilitation of the patient was successfully completed with installation of a dental prosthesis 6
months following implant placement. This proof-of-concept clinical report used an evidence-based
approach for the cell transplantation protocol used and is the first to describe a cell therapy for cra-
niofacial trauma reconstruction. STEM CELLS TRANSLATIONALMEDICINE 2014;3:1495–1503
INTRODUCTION
Inadditiontobruises,hematomas,and lacerations,
dentoalveolar injuries are the most common inju-
ries that occur in the facial region, accounting for
50% of the injuries for those seeking emergency
treatment for head and neck injuries [1–3]. The
resulting functional and aesthetic deficiencies
from the loss of teeth andassociated jawbone sup-
port due to these injuries are debilitating and very
difficult to treat. The current standard-of-care pro-
tocol for advanced craniofacial reconstruction in-
volving the oral cavity involves the use of large
autogenous “block” bone grafts, whereby the do-
nor boneblocksof boneareharvested from intrao-
ral sites (mandibular ramus or symphysis) or
extraoral sites (iliac crest, tibia) [4–7]. Although
advanced grafting procedures have historically
demonstrated varying degrees of success, major
limitations are that they require two surgical
sites (donor and recipient) and are often associ-
ated with long postoperative healing periods,
moderate to severe discomfort during healing,
tissuemorbidity in the donor site, and prolonged
sensory disturbances in the donor site.
Stem cell therapy is an emerging strategy that
can potentially be used for the reconstruction of
craniofacial deficiencies [8, 9]. Because cell-
therapy approaches often involve the use of
a polymer material to deliver cells to the defect
area, the success of these approaches is heavily
dependent not only on thepolymer and cells used
but also the conditions under which they are
used. Despite many in vitro and in vivo studies
designed to evaluate and optimize the cell attach-
ment and biocompatibility of different materials,
there is no clinical evidence of efficacy to support
these data. In contrast, in the limited clinical
reports investigating a cell-transplantation ap-
proach to regenerating craniofacial tissue, the
clinical protocols and conditions used to deliver
the cells are either not well described or not well
justified [10–14].
In a randomized controlled clinical trial, our
group recently reported the use of a gelatin
sponge to deliver stem cells into small, localized,
oral bone defects created following tooth re-
moval [15]. Although results were favorable,
the use of this sponge material as a cell carrier
is not suitable for regeneration of large oral and
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craniofacial defects. b-Tricalcium phosphate (b-TCP) has more
ideal properties as a cell carrier for addressing larger,more severe
bone defects because it has rigid structural properties and is
osteoconductive, which facilitates bone growth [16, 17]. Clini-
cally, it has been used as a bone-graft substitute material in very
limited orthopedic indications and in small, localized bone defi-
ciencies around teeth [18, 19]. Recently, its use as a cell carrier
for autologous adipose-derived stem cells has also been reported
with the combined use of recombinant human bone morphoge-
netic protein-2 to treat craniofacial defects [14]. Nonetheless, to
date, there has beenno reported clinical investigation of its use as
a scaffold for a stand-alone cell therapy in the treatment of large
craniofacial deficiencies.
We report a stem cell therapy to reconstruct the upper jaw of
a patient who lost front teeth and associated bone tissue follow-
ing a severe traumatic injury to the face.b-TCPwas used as a scaf-
fold to deliver the cells to the jawbone defect, and following 4
months of healing, sufficient bone was regenerated to insert oral
implants and restore them with dental prosthetics. In addition,
the clinical conditions for cell attachment and survival were opti-
mized for this cell-transplantation approach.
MATERIALS AND METHODS
Patient
Following U.S. Food and Drug Administration and University of
Michigan institutional review board approval to conduct a cell-
therapy study for theoral reconstructionof traumatic craniofacial
injuries, a 45-year-oldwoman presented to the clinic following an
injury in which she suffered a traumatic blow to the face. The in-
jury occurred 5 years prior to her initial presentation. and as a re-
sult of the injury, seven teeth (four in the anterior segment of the
upper jaw and three in the anterior segment of the lower jaw)
were avulsed and lost.Moreover, 75% of the supporting jawbone
and soft tissue surrounding these teeth were also lost as a result
of the injury. Consequently, the patient had severe oral-facial
functional and aesthetic deficiency. Due to inadequate alveolar
bone as a result of the injury, the patient was not a candidate
for rehabilitation with oral implant therapy without advanced re-
constructive bone-grafting procedures being performed. The pa-
tient was wearing an ill-fitting removable dental prosthesis on
initial presentation and was deemed eligible for participation in
the study.
Cell-Seeding Efficiency and Viability Studies
The production of ixmyelocel-T (tissue repair cells or ixmyelocel-
T; Aastrom Biosciences, Ann Arbor, MI, http://www.aastrom.
com) has been described previously [20]. Briefly, a bone marrow
aspiration of the posterior ilium was performed under conscious
sedation and local anesthetic. Collected marrow was transferred
to a sterile blood bag, and bone marrow mononuclear cells
(BMMNCs) were purified by Ficoll density gradient centrifuga-
tion. BMMNCs were then inoculated into a bioreactor, which is
a proprietary computer-controlled, automated cell processing
unit (AastromReplicell system;AastromBiosciences). This system
incorporates single-pass perfusion in which fresh medium flows
slowly over cellswithout retention ofwastemetabolites or differ-
entiating cytokines. The culturemediumconsists of Iscove’smod-
ified Dulbecco’s medium, 10% fetal bovine serum, 10% horse
serum, and 5 mM hydrocortisone. After cultivation for 12 days
at 37°C in 5% CO2 with a ramped continuous medium perfusion
schedule, the ixmyelocel-T product was harvested by trypsiniza-
tion, washed in a physiologic buffer, and collected into a sterile
bag for storage until the time of transplantation. The cells were
composed of a mixture of bone marrow-derived cells including
expanded CD90+ mesenchymal stem cells, CD14+ monocytes/
macrophages, andmononuclear cells from the original bonemar-
row aspirate [21, 22]. The cell population from this patient con-
sisted of 26% CD90+ cells and 15% CD14+ monocytes and had
a final concentration of 14.1 million cells per milliliter with cell vi-
ability of 91%. The primary purpose for obtaining these cells was
their use in the clinical treatment of the bone defect; however,
a specific section of the informed consent document obtained
the patient’s permission to use and/or store “excess” cells and/
or bonemarrow (if available) for additional laboratory or preclin-
ical studies.
For the cell-seeding and viability studies, T -150 flasks con-
taining 90% confluent cell populations of ixmyelocel-T were
trypsinized and counted. Cells were seeded onto equal volumes
ofb-TCP (Cerasorb; CurasanAG, Kleinostheim,Germany, http://
www.curasan.de) particles (1:1 ratio of cell suspension to vol-
ume b-TCP) and allowed to incubate at either room tempera-
ture (RT) or on ice (4°C). After 15, 30, and 60 minutes, the
residual cell suspension from the respective condition was col-
lected, and the number of cells remainingwas counted. The cell-
seeding efficiency was an indirect measure of the number of
cells that attached to the b-TCP particles. It was calculated
through an assumption of a constant number of cells for seeding
and deduction of the floating cells from this constant number
to get the number of seeded cells (efficiency). Cell viability
was measured as cell survival, determined through the dye ex-
clusion method of trypan blue staining of the remaining or
floating cells following incubation with the b-TCP and counting
this proportion of cells relative to the total number of
floating cells during the three respective time frames at RT
and at 4°C.
Cell Therapy, Regenerative Analyses, and
Oral Reconstruction
A cone beam computed tomography (CBCT) radiographic scan
was performed to volumetrically evaluate the upper jawbone
deficiency and generate three-dimensional reconstructions
of the upper jaw. Under conscious sedation and local anesthe-
sia, an intraoral full-thicknessmucoperiosteal flapwas elevated
to expose themargins of thebony defect in theupper jaw. In the
operating room, approximately 107 cells in suspension were
incubated with b-TCP at RT 30 minutes prior to being adminis-
tered to the defect site. Following clinical open bone measure-
ments of the width of the alveolar bone, the defect site was
prepared to receive the graft by creating small osteotomies
penetrating through the outer cortical layer of bone to facili-
tate vascular infusion of the graft during healing. Four 8-mm
“tenting” screws were used to help stabilize the b-TCP par-
ticles, and theb-TCPwas thenplacedandcoveredwith a resorb-
able collagen membrane (Conform collagen; Ace Surgical
Supply, Inc., Brockton, MA, http://www.acesurgical.com) to
help contain the grafted b-TCP/cell construct. In addition,
4-0 sutures were used to approximate the tissues, and the
area was allowed to heal for 4 months. A second CBCT scan
was performed immediately following grafting. Postoperative
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medications included an antibiotic, a corticosteroid, and an an-
algesic for pain management.
Four months following placement of the graft, a third CBCT
was performed to evaluate the presence of mineralized tissue
in the grafted area prior to implant placement. Following the im-
aging, the areawas surgically re-entered for the placement of oral
implants. During re-entry, clinical bone measurements were
recorded, and a bone biopsy was performed in an area of the pre-
viously grafted region. This tissuebiopsywasprocessed formicro-
computed tomography (micro-CT) and histological analysis, as
described previously [23]. Oral implants were placed in the
grafted sites and allowed to heal underneath the gingival tissue
for 6 months. At 6 months, the implants were uncovered, and
a dental prosthesis was engineered and installed to connect to
the oral implants. This study is registered with ClinicalTrials.gov
identifier CT00755911.
Statistical Analysis
Statistical analysis was performedwith the use of InStat software
(GraphPad Software, Inc., San Diego, CA, http://www.graphpad.
com). All data were plotted as mean 6 SEM unless otherwise
noted. One-way analysis of variance was performed for the
cell-seeding efficiency and cell-viability studies with Bonferroni-
corrected, post hoc, two-tailed t tests to determine statistically
significant differences between groups. Statistical significance
was defined as p, .05.
RESULTS
Cell-Seeding Efficiency
The time frame needed to achieve the highest cell attachment
to b-TCP was determined in our cell-seeding efficiency studies
Figure 1. Cell-seeding efficiency of b-tricalcium phosphate (b-TCP). (A): The overall cell-seeding efficiency is shown at different time intervals
(15, 30, and60minutes) following seedingof the scaffoldwith cells. (B):Thecell-seedingefficiency at thedifferent time intervalswas stratifiedby
the temperature at which the cells were allowed to incubate with the scaffold. (C): SEM images at low and high magnification showing the
distribution of cells and cell attachment to one b-TCP particle (individual particle sizes ranged from 500 to 1,000 mm). p, p , .05 relative to
the 15-minute condition. Abbreviation: RT, room temperature.
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(Fig. 1A). Cell-seeding efficiency ofb-TCP following 15minutes of
incubation with cells was 60%, with a significant increase to 81%
following 30minutes of incubation (p, .05). Therewas no differ-
ence in the seeding efficiency between 30 minutes and 1 hour of
incubation. In addition, when evaluating the effect of tempera-
ture on cell-seeding efficiency, therewas no difference in seeding
efficiency at 4°C relative to room temperature at the three time
points evaluated (Fig. 1B). SEM images show diffuse distribution
and attachment of the cells to one particle (500- to 1,000-mmpar-
ticle sizes) of thegraftmaterial following 30minutes of incubation
at room temperature (Fig. 1C).
Cell Viability During Cell Seeding
Another important variable in thecontext of cell therapy is thecell
viability throughout the process of cell seeding and transplanta-
tion. Cell viability was evaluated in a similar manner to cell-
seeding efficiency, at three different time points (15, 30, and
60 minutes) and two temperatures (RT, 4°C). Between the three
time points evaluated, cell survival was no different, between
88% and 94% (Fig. 2A). However, when stratifying for tempera-
ture, there was a significant decrease (p , .05) in cell survival
when incubated at RT for 1 hour relative to incubation at RT
for 30minutes orwhen incubatedat4°C for 1hour (Fig. 2B).When
at 4°C, the time frame of incubation did not affect cell survival.
Overall, the optimum conditions for cell survival were 30-minute
incubations at RT or 4°C or a 60-minute incubation period at 4°C.
Clinical Cell Transplantation
The protocol for transplantation of the cells used the optimized
attachment and survival conditions, which were to maintain
the cells on ice (4°C) until 30 minutes prior to transplantation,
at which time they were incubated with the b-TCP at RT. During
this period inwhich thecellswere incubating, thegingival flapwas
reflected to expose the underlying bone, and measuring instru-
ments were used to measure the horizontal dimension of the al-
veolar ridge, whichwas 3mm (Fig. 3A–3D). In a healthy dentition,
horizontal ridge width of this area of the maxilla normally ranges
from 8 to 12 mm, and to securely place and stabilize a dental im-
plant, 7–8 mm is the minimum width required. Tenting screws
were placed in the area to receive the graft andwere used to help
consolidate the graft material and prevent collapse of the over-
lying collagen membrane and soft tissue following closure of
the flap (Fig. 3E, 3F). The graft was applied to the deficient area,
and an additional 0.5mL of the cell suspensionwas added follow-
ing placement of the graft into the site (Fig. 3G, 3H). A barrier
membrane was placed over the graft to prevent soft tissue infil-
tration into the graft during the early stage of healing (Fig. 3I), and
the tissues were approximated completely (Fig. 3J).
Radiographic, Clinical, and Histological Analyses of
Jawbone Reconstruction
The 75%horizontal bone deficiency in the upper jaw in the area of
the missing teeth was clearly evident radiographically and using
volumetric evaluation of three-dimensional reconstructed CBCT
images prior to treatment (Fig. 4A). Immediately after grafting,
a second CBCT was performed and showed a 10- to 12-mm in-
crease in horizontal width of the jawbone (Fig. 4B). Four months
after grafting and immediately before implant placement, a third
CBCT was performed and showed that, compared with immedi-
ately following grafting, there was an overall 25% reduction of
the initial graftedwidth (Fig. 4B, 4C).However, relative to theorig-
inal jawbone deficiency, there was a net 5- to 6-mm horizontal
gain in width of the jawbone, resulting in 80% regeneration of
the original jawbone deficiency (Fig. 4A, 4C).
Four months following healing, the grafted site was re-
entered for oral implant placement, and there was clinically ap-
parent evidence of bone regenerationwith anewhorizontal ridge
width of 8–9 mm (Fig. 5A, 5B). Oral implants were then stably
placed in the previously grafted sites and biomechanically tor-
qued to standard-of-care guidelines of 35 newton centimeters
(Fig. 5C, 5D). Implants were left submerged under the gingival tis-
sue (Fig. 5E, 5F) for 6months of healing.Micro-CT and histological
evaluation of the bone biopsy harvested from the area of the
grafted region revealed highly vascularized,mineralized tissue in-
dicative of bone formation and 80% of theb-TCPmatrix resorbed
(Fig. 5G, 5H). Full functional and aesthetic restoration of the area
was completed 6 months following implant placement, with the
engineering and placement of an oral implant-supported dental
prosthesis (Fig. 6).
DISCUSSION
Regenerativemedicine aims to use tissue engineering and biomi-
metic strategies to functionally restore and replace damaged and
lost tissue [24]. In this report, we describe a cell therapy for the
oral reconstruction of a patient who lost teeth and supporting
Figure 2. Cell viability following seeding onb-tricalcium phosphate.
(A): Cell survival at different time intervals following loading of the
scaffold is shown. (B): Cell survival at the different time intervals
was stratified by the temperature at which the cells weremaintained
during the respective time intervals during which the cells were
allowed to incubate with the scaffold. p, p, .05 between conditions.
Abbreviation: RT, room temperature.
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jawbone tissue as a result of a traumatic injury to the face. In ad-
dition, optimized parameters for cell attachment and survival
were defined for the cell transplantation protocol used in this ap-
proach. To date, this study represents themost advanced cranio-
facial trauma reconstruction using a stem cell-based therapy for
oral rehabilitation involving oral implants.
Important considerations in regenerative medicine involving
cell-transplantation protocols are the conditions under which
cells are delivered [9, 25]. These parameters are of even greater
importance if biomaterials are used for delivery of cells. b-TCP
has been used as a bone graft substitute material to fill in small,
localized bone deficiencies around teeth and in very limited
Figure 3. Cell transplantation procedure. Front view (A) and top view (B) of the initial clinical presentation showing severe hard and soft tissue
alveolar ridgedefects of theupper jaw. Followingelevationof a full-thickness gingival flap, the images show front view (C) and topview (D)of the
severelydeficient alveolar ridge, clinicallymeasuring awidthofonly2–4mm.Front view (E)and topview (F)of theplacementof “tenting” screws
inpreparationof thebony site to receive thegraft. Placementof theb-tricalciumphosphate (seededwith the cells 30minutesprior toplacement
at room temperature) into the defect (G), with additional application of the cell suspension following placement of the graft in the recipient site
(H). Placement of a resorbable barriermembrane (I) to stabilize and contain the graftwithin the recipient site, and top view (J)of primary closure
of the flap.
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orthopedic indications. However, there have been no reported
clinical investigations of its use as a scaffold for a stand-alone cell
therapy to treat large craniofacial deficiencies. In a case series,
Sandor and colleagues recently reported its use as a scaffold to
deliver adipose-derived stem cells to jawbone defects in combi-
nation with large doses of BMP-2 [14]. These defects were sec-
ondary to tumor resective surgery, and although radiographic
outcomes were deemed favorable, limited data were presented
relative to the clinical, functional, and histological integrity of the
regenerated jawbone tissue.We usedb-TCP in our study as a car-
rier to deliver the cells because tricalcium phosphates are highly
biocompatible, havebeenshownto supportosteogenic activityof
mesenchymal stemcells, and have beenused as a delivery vehicle
in a number of animal studies in which cell transplantation has
been used [16, 26–28]. Krebsbach and colleagues reported that
relative to other biomaterials commonly used clinically, such as
gelatin sponges and demineralized bone matrix, tricalcium phos-
phates most consistently yield bone formation in vivo when used
as a delivery vehicle for mesenchymal stem cells [27]. Although
this material has favorable characteristics for cell proliferation,
differentiation, and in vivo bone formation, studies have not eval-
uated or reported the cell-seeding efficiency (i.e., how efficiently
cells attach tob-TCP) of the cells whenb-TCP is used as a delivery
vehicle. Cell attachment and seeding efficiency can have signifi-
cant influence on the regenerative response in determining the
number of cells that reach the regenerative site [29]. Our study
determined that the minimum time needed for incubation of
the cells to allow the greatest cell attachment (.81%) was 30
minutes.We did not evaluate time points longer than 60minutes
because cell seeding occurs at the time of surgical application of
the cells. Hence, incubation times greater than 60minutes would
affect the clinical protocol and prolong the surgical procedure,
which could have adverse consequences on outcomes (e.g.,
increased risk of infection, increased bleeding, increased inflam-
mation). Another important clinical consideration for cell trans-
plantation, particularly if there is an incubation period prior to
delivery of the cells, is the incubation temperature. During the in-
cubation time frames of 15, 30, and 60 minutes, it was determined
Figure 4. Cone-beam computed tomography (CBCT) scans. CBCT scans were used to render three-dimensional reconstructions of the anterior
segment of the upper jaw and cross-sectional (top view) radiographic images to show volumetric changes of the upper jaw at three time points.
(A, B): The initial clinical presentation shows 75% jawbone width deficiency. (C, D): Immediately following cell therapy grafting, there is full
restoration of jawbone width. (E, F): Images show 25% resorption of graft at 4 months and overall net 80% regeneration of the original
ridge-width deficiency.
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that the cell-seeding efficiency was no different if cells were incu-
bated at 4°C or at room temperature.
Regardless of the material or modality used to deliver cells
during the process of cell transplantation, it is clear that cell-
seeding efficiency is an important determinant of the number
of cells that reach a regenerative site. Despite the impact of seed-
ing efficiency on successful regenerative outcomes, the viability
of the cells that aredelivered is evenmorecritical to theoutcomes
achieved with this approach [30]. Although temperature did not
affect cell-seeding efficiency in our study, it is well established
that temperature can have a profound effect on cell viability. In
various tissue-grafting and organ-transplantation protocols, it is
often highly desirable to maintain tissue specimens at 4°C (on
ice) until ready for application or placement in the recipient site
[31–34]. In regenerative cell-transplantation strategies involving
stem cells, although important, this parameter has not been thor-
oughly examined. In our study, we found that if cells were incu-
batedwithb-TCP for 30minutes or less, survival was not affected
by the incubation temperature (room temperature vs. 4°C). If
cells were incubated for 1 hour, cell survival was significantly
greater when the cells were incubated at 4°C relative to when in-
cubation occurred at room temperature. Beyond 30 minutes, it
was determined that cells should be maintained at 4°C prior to
delivery to achieve the greatest cell viability.
Using a different biomaterial for cell delivery, our group re-
cently completeda randomizedcontrolled clinical trial investigating
Figure 5. Surgical re-entry of the grafted site and implant placement. Following elevation of a full-thickness gingival flap, front view (A) and top
view (B) of the treated site reveal regenerated tissue and a reconstructed alveolar ridge clinically measuring a width of 8–10mm. Front view (C)
and top view (D)of theplacement of dental implants in the regenerated sites. (E, F): Primary closure of the site. Abone core biopsywas retrieved
fromoneof the regenerated sites todetermine thepresenceofmineralized tissuewithmicro-computed tomography analysis (G)and to confirm
the histomorphometric appearance of bone tissue histologically (H)with hematoxylin and eosin staining (green arrows highlight residual b-tri-
calcium phosphate, yellow arrows highlight bone tissue; magnification: 340 and 3100).
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a similar cell-therapy approach in the treatment of small, local-
ized, alveolar bone defects created following tooth removal
[15]. The extraction socket defect created in alveolar bone follow-
ing tooth removal heals, to an extent, without intervention and
thus serves as a natural clinical model of bone healing [35]. In
our previous study, ixmyelocel-T was administered to these ex-
traction socket defects at the time of tooth removal, and delivery
of the cells resulted in acceleration of the innate bone regenera-
tion within the localized defect. Despite these promising results,
because there is innate bone regeneration following tooth re-
moval, this model does not serve as an ideal model for evaluating
denovobone regeneration. In addition, this studywasperformed
as a proof of concept to demonstrate safety and efficacy of the
approach; however, from a feasibility standpoint, cell therapy
would not be used in such a localized defect following removal
of a tooth. The more appropriate application for this cell therapy
would be in more complex and severe craniofacial defects, as of-
ten occur following oral-facial trauma. A severe defect resulting
from a traumatic injury would not naturally resolve without sig-
nificant intervention and also results in significant functional
and aesthetic deficiencies. As such, these defects typically require
advanced bone-grafting procedures with autogenous blocks of
bone or guided bone regenerative (GBR) procedures [36]. Similar
to our surgical procedure, the GBR approach uses a protective
barrier membrane to cover the allogeneic or alloplastic graft ma-
terial during healing. However, following GBR for large recon-
structions of alveolar bone, most protocols allow a healing
period, minimally, of 6–8months before re-entry for oral implant
placement [37]. Throughdeliveryof100million cells usinga tissue
engineering cell-therapy approach, inonly 4monthswewereable
to regenerate 80% of the original jawbone deficiency, which was
sufficient to stably place oral implants to biomechanically support
a dental prosthesis.
CONCLUSION
Cell survival and seeding efficiency in the context of tissue engi-
neering and cell-therapy strategies are critical parameters for
success that have not been rigorously examined in a clinical con-
text. This study defined optimized conditions for these parame-
ters using an autologous stem cell therapy to successfully treat
a patient who had a debilitating craniofacial traumatic defi-
ciency. To our knowledge, there have been no other clinical
reports of cell therapy for the treatment of craniofacial trauma
defects. This clinical report serves as solid foundation on which
to develop more expanded studies using this approach for the
treatment of larger numbers of patients with other debilitating
conditions (e.g., congenital disorders) to further evaluate effi-
cacy and feasibility.
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